Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer

Clinical Cancer Research

Volumn 20, Issue 21, 2014, Pages 5496-5506

  Casagrande, Naike ^a   Celegato, Marta ^a   Borghese, Cinzia ^a   Mongiat, Maurizio ^a   Colombatti, Alfonso ^a,b   Aldinucci, Donatella ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CARBOPLATIN; CASPASE 3; CASPASE 8; CASPASE 9; CD133 ANTIGEN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LIPOPLATIN; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG; ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; CASPASE; EGFR PROTEIN, HUMAN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; LIPOSOME; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; BIOLOGICAL ACTIVITY; CANCER INHIBITION; CANCER STEM CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN METABOLISM; TUMOR GROWTH; TUMOR SPHEROID; TUMOR XENOGRAFT; UPREGULATION; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; OVARIAN NEOPLASMS; TUMOR CELL LINE; TUMOR INVASION;

ALBUMINS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOPROTEINS; HUMANS; LIPOSOMES; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PACLITAXEL; PEPTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPHEROIDS, CELLULAR; UP-REGULATION;

EID: 84910052428     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0713     Document Type: Article

References (50)

1. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013;10:211-24.
2. Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014;5:e1257.
3. Zalba S, Garrido MJ. Liposomes, a promising strategy for clinical application of platinum derivatives. Expert Opin Drug Deliv 2013;10:829-44.
4. Liu D, He C, Wang AZ, Lin W. Application of liposomal technologies for delivery of platinum analogs in oncology. Int J Nanomedicine 2013;8:3309-19.
5. Seetharamu N, Kim E, Hochster H, Martin F, Muggia F. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res 2010;30:541-5.
6. Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J Drug Deliv 2012;2012:581363.
7. Farhat FS, Temraz S, Kattan J, Ibrahim K, Bitar N, Haddad N, et al. A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer. Clin Breast Cancer 2011;11:384-9.
8. Casagrande N, De Paoli M, Celegato M, Borghese C, Mongiat M, Colombatti A, et al. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer. Gynecol Oncol 2013;131:744-52.
9. Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 2005;25:3031-9.
10. Boulikas T. Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin. Lipoplatin as a chemotherapy and antiangiogenesis drug. Cancer Ther 2007;5:351-76.
11. Lee JM, Mhawech-Fauceglia P, Lee N, Parsanian LC, Lin YG, Gayther SA, et al. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Invest 2013;93:528-42.
12. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
13. Cattaruzza L, Fregona D, Mongiat M, Ronconi L, Fassina A, Colombatti A, et al. Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts. Int J Cancer 2011;128:206-15.
14. Vinci M, Box C, Zimmermann M, Eccles SA. Tumor spheroid-based migration assays for evaluation of therapeutic agents. Methods Mol Biol 2013;986:253-66.
15. Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol 2009;113:143-8.
16. Bandekar A, Karve S, Chang MY, Mu Q, Rotolo J, Sofou S. Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin. Biomaterials 2012;33:4345-52.
17. Dolznig H, Rupp C, Puri C, Haslinger C, Schweifer N, Wieser E, et al. Modeling colon adenocarcinomas in vitro a 3D co-culture system induces cancer-relevant pathways upon tumor cell and stromal fibroblast interaction. Am J Pathol 2011;179:487-501.
18. Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA, Harrap KR. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines. Cancer Res 1992;52:6188-93.
19. Brozovic A, Ambriovic-Ristov A, Osmak M. The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit Rev Toxicol 2010;40:347-59.
20. Mahmood DF, Abderrazak A, El HK, Simmet T, Rouis M. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal 2013;19:1266-303.
21. Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 2011;29:3628-35.
22. Pisano C, Cecere SC, Di NM, Cavaliere C, Tambaro R, Facchini G, et al. Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer. J Drug Deliv 2013;2013:898146.
23. Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. Drug Des Devel Ther 2012;6:371-84.
24. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2011;122:111-5.
25. Glaysher S, Bolton LM, Johnson P, Atkey N, Dyson M, Torrance C, et al. Targeting EGFR and PI3K pathways in ovarian cancer. Br J Cancer 2013;109:1786-94.
26. Sugihara E, Saya H. Complexity of cancer stem cells. Int J Cancer 2013;132:1249-59.
27. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer 2012;130:29-39.
28. Sodek KL, Ringuette MJ, Brown TJ. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer 2009;124:2060-70.
29. Chahinian AP, Mandeli JP, Gluck H, Naim H, Teirstein AS, Holland JF. Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. J Surg Oncol 1998;67:104-11.
30. Koch M, Krieger ML, Stolting D, Brenner N, Beier M, Jaehde U, et al. Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling. Biochem Pharmacol 2013;85:1077-90.
31. Stolting DP, Borrmann M, Koch M, Wiese M, Royer HD, Bendas G. How liposomal Cisplatin overcomes chemoresistance in ovarian tumour cells. Anticancer Res 2014;34:525-30.
32. Wu CC, Bratton SB. Regulation of the intrinsic apoptosis pathway by reactive oxygen species. Antioxid Redox Signal 2012;19:546-58.
33. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
34. Liu Y, Li Y, Yu S, Zhao G. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents. Curr Drug Targets 2012;13:1432-44.
35. Powis G, Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 2007;7:392-7.
36. Witte AB, Anestal K, Jerremalm E, Ehrsson H, Arner ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 2005;39:696-703.
37. Tillmanns TD, Lowe MP, Walker MS, Stepanski EJ, Schwartzberg LS. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol 2013;128:221-8.
38. Noske A, Schwabe M, Weichert W, Darb-Esfahani S, Buckendahl AC, Sehouli J, et al. An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer 2011;11:294-11.
39. Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol 2014;32:320-6.
40. Nakayama K, Nakayama N, Katagiri H, Miyazaki K. Mechanisms of ovarian cancer metastasis: biochemical pathways. Int J Mol Sci 2012;13:11705-17.
41. Liebscher CA, Prinzler J, Sinn BV, Budczies J, Denkert C, Noske A, et al. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. Hum Pathol 2013;44:1465-71.
42. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010;9:3186-99.
43. Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A, et al. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol 2013;130:579-87.
44. Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov 2011;1:144-57.
45. Kwon MJ, Shin YK. Regulation of ovarian cancer stem cells or tumor-initiating cells. Int J Mol Sci 2013;14:6624-48.
46. Chahinian AP, Norton L, Holland JF, Szrajer L, Hart RD. Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma. Cancer Res 1984;44:1688-92.
47. Stathopoulos GP, Stathopoulos J, Dimitroulis J. Two consecutive days of treatment with liposomal cisplatin in non-small cell lung cancer. Oncol Lett 2012;4:1013-6.
48. Stathopoulos GP, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K, Michalopoulou P. Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother Pharmacol 2011;68:945-50.
49. Mylonakis N, Athanasiou A, Ziras N, Angel J, Rapti A, Lampaki S, et al. Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer 2010;68:240-7.
50. Stathopoulos GP, Antoniou D, Dimitroulis J, Michalopoulou P, Bastas A, Marosis K, et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann Oncol 2010;21:2227-32.